

18th World Hematology Congress | March 16-17, 2020 at London, UK

Gaëlle Dzangue-Tchoupou

Department of Hematology, Sorbonne University, France, E-mail: gaelle.dzangue-tchoupou@cea.fr

Globally the hematology diagnostics market is growing at a CAGR of 5.9% for the period from 2018 to 2026. Based on the product type the hematology analyzer segment shows lucrative growth with enhanced applications in the diagnostics industry. An increasing number of diagnostic centers availability of automated analyzers with enhanced applications and increasing test volumes will contribute to the overall growth of the hematology diagnostics market. Major players in this vertical are Abbott Laboratories Bio-Rad Laboratories Inc. Siemens Healthineers Mindray Medical International Limited Danaher Corporation Hoffmann-La Roche Ltd. Nihon Kohden Corporation Drew Scientific Sysmex Corporation EKF Diagnostics Boule Diagnostics HORIBA Diatron MI Zrt. and others.


The global hematology diagnostics market is growing significantly due to the rising prevalence of blood-related disorders cancer and infectious diseases. Additionally increasing awareness of these targeted diseases along with its diagnosis and screening by diagnostic centers hospitals private firms and social media are the key factors driving the market growth internationally. Currently more than 1.3 million individuals in the U.S. are living with leukemia myeloma or lymphoma.

[Hematology](#) consumables hold the major share in the hematology diagnostics market in 2017. New product launch acquisitions and partnerships among top players in the developed nations are factors promoting market growth. For instance in June 2017 Abbott Laboratories declared the availability of CP3000 coagulation analyzer by Sekisui Diagnostics in the Asia Pacific Europe and the Middle East. Moreover in April 2018 Danaher Corporation received CE Mark approval of its DxH 520 hematology analyzer. Hematology testing products has gained extensive acceptance worldwide mainly by hospitals and diagnostic centers. Demand for automated hematology instruments in the emerging nations is gaining traction slowly along with enhanced diagnosis services. Limited availability of new products less

awareness regarding blood disorders and unstructured medical care in developing nations will restrain market growth globally. However enhanced productivity of test results via automation techniques along with flow cytometers and sales of hematology instruments with high throughput screening will drive the market growth during the forecast period.

The market in the Asia Pacific shows promising growth due to new technology expansion along with government funding. Moreover increasing prevalence of blood disorders demand for point of care services and boom in the biotechnology industry are key factors driving the overall market growth.

The global hematology diagnostics market size was estimated at USD 5.96 billion in 2017. It is anticipated to expand at a CAGR of 5.85% over the forecast period. The factors such as increasing prevalence of blood disorders coupled with increasing awareness about these disorders and presence of sophisticated & advanced technologies are anticipated to propel the market growth. According to an article published by Bristol-Myers Squibb nearly 1 million new cases of blood cancer are expected to be diagnosed by 2020 which is anticipated to account for nearly 6.0% of all new cancer. Furthermore a significant number of the world population have different hemoglobinopathies. High prevalence of blood disorders such as thalassemia is anticipated to boost the demand for [hematology testing](#).



Scope & Importance:

Haematology involves the diagnosis and treatment of patients who have disorders of the blood and bone marrow. Whilst a major part of a haematologist's time is spent in providing direct clinical care to patients, diagnostic work in the laboratory is also a significant part of their work.

Haematology is the specialty responsible for the diagnosis and management of a wide range of benign and malignant disorders of the red and white blood cells, platelets and the coagulation system in adults and children. A haematologist will be needed to consider such issues; they can advise on what tests have already been performed and whether there are any further tests which should be undertaken.

Related Companies/Industries:

- Abbott Laboratories
- Product Portfolio
- Bio-Rad Laboratories Inc
- Siemens Healthineers
- Mindray Medical International Limited
- F Hoffmann-La Roche Ltd
- Danaher Corporation
- Nihon Kohden Corporation
- Drew Scientific
- Sysmex Corporation
- EKF Diagnostics
- Boule Diagnostics

- HORIBA
- Diatron MI Zrt

Related Associations

- European Society of Hematology
- British Society of Hematology
- International Society of Hematology
- European Society of Paediatric Hematology Oncology
- Sociedad Espanola de Hematology Hemotherapy
- Asian Oncology Nursing Society (AONS)
- Asian Society of Gynecologic Oncology (ASGO)
- Asian Society of Head & Neck Oncology (ASHNO)
- Federation of Asian Organization for Radiation Oncology (ARO)
- American Society of Hematology
- International Society for Laboratory Hematology
- The Canadian Hematology Society
- Michigan Society of Hematology
- American Society of Clinical Oncology
- American Cancer Society (ACS)
- American Association for Cancer Research (AACR)
- International Agency for Research on Cancer (IARC)
- American Society of Clinical Oncology (ASCO)
- Emirates Society of Hematology
- Saudi Society for Hematology
- Hematology Society of Australia and New Zealand
- Malaysian Society of Hematology
- American Hematology Association.
- European Society for Gene and Cell Therapy
- International Society for Stem Cell Research (ISSCR)
- UK Oncology Nursing Children's Cancer and Leukemia Group Society
- European Society of Oncologic Imaging
- European Association for Cancer Research